Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Advertisement
Urothelial Carcinoma Knowledge Hubs
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Roundtable Discussions
The panel concludes with a discussion on the early use of PARP inhibitors in patients with DNA repair mutations like BRCA1/2.
The panel delves into how de novo metastases signal more aggressive prostate cancer biology.
The panel weighs the role of next-generation sequencing and emphasizes how SPOP, TP53, and RB1 guide treatment decisions.
The panel considers the evolving management of oligometastatic prostate cancer, highlighting the role of MDT.
The panel reviews treatment options for newly diagnosed mHSPC, comparing data from key doublet trials.
The panel explores scenarios where PSMA PET may not be needed, as well as limitations of conventional imaging in trials.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhDEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.